SOURCE-LINKED STUDY SUMMARY
Mitochondrial-derived peptide MOTS-c rescues vascular endothelial damage via PLA2G6 in diabetic retinopathy
Abstract summarizedQuality not appraised
- What was studied
- Preclinical experiments examined whether MOTS-c protects retinal blood vessels during diabetic injury.
- Who / model studied
- Human retinal endothelial cells exposed to high glucose and a streptozotocin-induced diabetic mouse model. No administered-human study.
- Studied dose & schedule
- MOTS-c treatment with genetic pathway experiments; dose, route, duration and sample sizes were not reported in the abstract.
- What the study found
- Endothelial barrier and mitochondrial measures improved. PLA2G6 increased, and its knockdown blocked protection, supporting a role for phospholipid regulation and lipid-peroxide handling.
- Limitations & context
- Abstract-based assessment of an early peer-reviewed accepted article, still subject to editing. These models do not establish improved human vision, general metabolic enhancement or clinical safety.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41420-026-03384-5